LAG3 抗体 (Extracellular Domain)
Our Local Distributor
北京 101111
Quick Overview for LAG3 抗体 (Extracellular Domain) (ABIN6992260)
抗原
See all LAG3 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- Extracellular Domain
-
纯化方法
- LAG-3 Antibody is supplied as protein A purified IgG1.
-
免疫原
- LAG-3 antibody was raised against the extracellular domain of human LAG-3
-
亚型
- IgG1 kappa
-
-
-
-
应用备注
-
LAG-3 antibody can be used for ELISA starting at 0.25 μ,g/mL. For Western blot start at 0.25 μ,g/mL. For Immunocytochemistry start at 1 μ,g/mL. For Immunofluorescence start at 10 μ,g/mL. For Immunohistochemistry start at 5 μ,g/mL. For Flow Cytometry start at 1 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples, Immunocytochemistry in human samples, Immunofluorescence in human samples and Flow Cytometry in human samples. All other applications and species not yet tested. -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 mg/mL
-
缓冲液
- LAG-3 Antibody is supplied in PBS containing 0.02 % sodium azide and 50 % glycerol.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- -20 °C,4 °C
-
储存方法
- LAG-3 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
-
别名
- LAG3
-
背景
- The lymphocyte activation gene-3 (LAG3) is a member of the immunoglobulin superfamily and binds MHC class II with high affinity (1), negatively regulating T-cell function and homeostasis (2). It is expressed in B, T, and NK cells, monocytes, and dendritic cells (3), and acts to regulate T cell expansion (4). LAG3 is also an important immune checkpoint protein, with anti-LAG3 antibodies activating T effector cells and affecting regulatory T cell functions. Furthermore LAG3 appears to act in a synergistic fashion with PD-1/PD-L1, suggesting that a dual antibody approach may prove useful in cancer immunotherapy.
-
分子量
-
Predicted: 55 kDa
Observed: 60, 70, 80 kDa -
基因ID
- 3902
-
NCBI登录号
- NP_002277
-
UniProt
- P18627
-
途径
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
抗原
-